Cargando…
Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise
To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E(2) (PGE(2)), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365786/ https://www.ncbi.nlm.nih.gov/pubmed/18475722 http://dx.doi.org/10.1155/S0962935196000336 |
_version_ | 1782154217077604352 |
---|---|
author | Croisier, J-L. Camus, G. Monfils, T. Deby-Dupon, G. Fafchamps, M. Venneman, I. Crielaard, J-M. Juchmès-Ferir, A. Lhermerout, C. Lamy, M. Deby, C. |
author_facet | Croisier, J-L. Camus, G. Monfils, T. Deby-Dupon, G. Fafchamps, M. Venneman, I. Crielaard, J-M. Juchmès-Ferir, A. Lhermerout, C. Lamy, M. Deby, C. |
author_sort | Croisier, J-L. |
collection | PubMed |
description | To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E(2) (PGE(2)), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isokinetic tests separated by a period of at least 6 weeks: once with placebo, and once with piroxicam (Feldene(®)). They were given one capsule containing either placebo or piroxicam (20 mg) per day for 6 days with initial doses given starting 3 days prior to isokinetic testing. Exercise consisted of eight stages of five maximal contractions of the knee extensor and flexor muscle groups of both legs separated by 1 min rest phases, on a Kin Trex device at 60(°)/s angular velocity. The subjective presence and intensity of DOMS were evaluated using a visual analogue scale immediately after, and 24 and 48 h after each test. The mean plasma concentration of PGE(2) measured at rest and after exercise was significantly lower in the group treated with piroxicam (p < 0.05). However, statistical analysis (two-way ANOVA test) revealed that exercise did not cause any significant change of mean plasma PGE(2) over time in either of the two groups. Eccentric work was followed by severe muscle pain in extensor and flexor muscle groups. Maximal soreness was noted 48 h postexercise. Serum creatine kinase activity and the serum concentration of myoglobin increased significantly, and reached peak values 48 h after exercise in both experimental conditions (p < 0.001). By paired t-test, it appeared that there were no significant differences in the serum levels of these two markers of muscle damage between the two groups at any time point. We conclude that: (1) oral administration of piroxicam fails to reduce muscle damage and DOMS caused by strenuous eccentric exercise; and (2) the hypothetical role of increased PGE(2) production in eccentric exercise-induced muscle damage, DOMS, and reduced isokinetic performance is not substantiated by the present results. |
format | Text |
id | pubmed-2365786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-23657862008-05-12 Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise Croisier, J-L. Camus, G. Monfils, T. Deby-Dupon, G. Fafchamps, M. Venneman, I. Crielaard, J-M. Juchmès-Ferir, A. Lhermerout, C. Lamy, M. Deby, C. Mediators Inflamm Research Article To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E(2) (PGE(2)), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isokinetic tests separated by a period of at least 6 weeks: once with placebo, and once with piroxicam (Feldene(®)). They were given one capsule containing either placebo or piroxicam (20 mg) per day for 6 days with initial doses given starting 3 days prior to isokinetic testing. Exercise consisted of eight stages of five maximal contractions of the knee extensor and flexor muscle groups of both legs separated by 1 min rest phases, on a Kin Trex device at 60(°)/s angular velocity. The subjective presence and intensity of DOMS were evaluated using a visual analogue scale immediately after, and 24 and 48 h after each test. The mean plasma concentration of PGE(2) measured at rest and after exercise was significantly lower in the group treated with piroxicam (p < 0.05). However, statistical analysis (two-way ANOVA test) revealed that exercise did not cause any significant change of mean plasma PGE(2) over time in either of the two groups. Eccentric work was followed by severe muscle pain in extensor and flexor muscle groups. Maximal soreness was noted 48 h postexercise. Serum creatine kinase activity and the serum concentration of myoglobin increased significantly, and reached peak values 48 h after exercise in both experimental conditions (p < 0.001). By paired t-test, it appeared that there were no significant differences in the serum levels of these two markers of muscle damage between the two groups at any time point. We conclude that: (1) oral administration of piroxicam fails to reduce muscle damage and DOMS caused by strenuous eccentric exercise; and (2) the hypothetical role of increased PGE(2) production in eccentric exercise-induced muscle damage, DOMS, and reduced isokinetic performance is not substantiated by the present results. Hindawi Publishing Corporation 1996-06 /pmc/articles/PMC2365786/ /pubmed/18475722 http://dx.doi.org/10.1155/S0962935196000336 Text en Copyright © 1996 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Croisier, J-L. Camus, G. Monfils, T. Deby-Dupon, G. Fafchamps, M. Venneman, I. Crielaard, J-M. Juchmès-Ferir, A. Lhermerout, C. Lamy, M. Deby, C. Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title | Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title_full | Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title_fullStr | Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title_full_unstemmed | Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title_short | Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
title_sort | piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365786/ https://www.ncbi.nlm.nih.gov/pubmed/18475722 http://dx.doi.org/10.1155/S0962935196000336 |
work_keys_str_mv | AT croisierjl piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT camusg piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT monfilst piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT debydupong piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT fafchampsm piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT vennemani piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT crielaardjm piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT juchmesferira piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT lhermeroutc piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT lamym piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise AT debyc piroxicamfailstoreducemyocellularenzymeleakageanddelayedonsetmusclesorenessinducedbyisokineticeccentricexercise |